The ASM sent a statement to ASM members on Dual Use Research of Concern and Biosafety.
The ASM has prepared a history related to select agents.
ASM provided comments to the Centers for Medicare & Medicaid Services (CMS) regarding Section 1834A, “Improving Policies for Clinical Diagnostic Laboratory Tests,” added to the Social Security Law by the Protecting Access to Medicare Act of 2014 (PAMA).
The ASM sent a letter to Senator Tom Harkin thanking him for the Accelerating Biomedical Research Act and his leadership regarding funding for the National Institutes of Health.
The ASM presented recommendations to the Centers for Medicare & Medicaid Services at its annual public meeting on payment levels for new tests to be included in the 2015 Clinical Laboratory Fee Schedule.